MIR200CHG and breast carcinoma: Furthermore, on conducting cisplatin drug sensitivity experiments, knockdown of MIR200CHG significantly decreases the IC50 of MCF7 cells from 1.25 ± 0.08 μg/mL to 0.12 ± 0.05 μg/mL, while overexpression of MIR200CHG increases the IC50 of MDA-MB-231 cells from 2.78 ± 0.09 μg/mL to 4.62 ± 0.14 μg/mL, indicating that MIR200CHG is involved in the drug resistance process of breast cancer cells (Fig. 2n, o).